Loading...
•
Dec 31, 2025
Veru Q1 2026 Earnings Report
Veru reported its fiscal 2026 first quarter financial results and clinical program progress, highlighting a decrease in net loss and operating loss from continuing operations, alongside a significant increase in cash and cash equivalents.
Key Takeaways
Veru Inc. reported a net loss of $5.3 million, or $0.26 per share, for the fiscal 2026 first quarter, a notable improvement from the $8.9 million net loss in the prior year. The company also saw a substantial increase in cash, cash equivalents, and restricted cash, reaching $33.0 million.
Net loss decreased to $5.3 million, or $0.26 per share, compared to $8.9 million, or $0.61 per share, in the prior year.
Operating loss from continuing operations decreased to $5.4 million from $10.2 million in the same period last year.
Cash, cash equivalents, and restricted cash significantly increased to $33.0 million as of December 31, 2025, from $15.8 million as of September 30, 2025.
Research and development expenses decreased to $1.3 million from $5.7 million in the prior year's quarter.
Forward Guidance
Veru plans to initiate the Phase 2b PLATEAU clinical trial for enobosarm in combination with semaglutide this calendar quarter, with interim analysis results anticipated in Q1 calendar year 2027. The trial aims to address weight loss plateaus and preserve lean mass in older patients with obesity.
Positive Outlook
- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity is on track to initiate this quarter.
- FDA has provided regulatory clarity for enobosarm, outlining two possible pathways for approval based on incremental weight loss or clinically beneficial preservation in physical function.
- FDA confirmed enobosarm 3 mg as an acceptable dosage for future clinical development.
- Improving bone mineral density (BMD) in postmenopausal women with obesity receiving GLP-1 RA at risk for bone fractures could be another primary endpoint with a clear regulatory pathway for enobosarm.
- The Phase 2b PLATEAU study is designed to assess enobosarm's ability to break through weight loss plateaus and preserve muscle mass and physical function.
Challenges Ahead
- The company's actual results could differ materially from forward-looking statements due to known and unknown risks and uncertainties.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...